Adverum Biotechnologies Inc
ADVM2.435USD
+0.115+4.96%
Horário de mercado （ET）Cotações atrasadas em 15 min
50.54MValor de mercado
PerdaP/L TTM
Mais detalhes de Adverum Biotechnologies Inc Empresa
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs.
Informações da empresa
Código da empresaADVM
Nome da EmpresaAdverum Biotechnologies Inc
Data de listagemJul 31, 2014
CEODr. Laurent Fischer, M.D.
Número de funcionários155
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 31
Endereço100 Cardinal Way
CidadeREDWOOD CITY
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal94063
Telefone16506491004
Sitehttps://adverum.com/
Código da empresaADVM
Data de listagemJul 31, 2014
CEODr. Laurent Fischer, M.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Setareh (Star) Seyedkazemi, Pharm.D.
Dr. Setareh (Star) Seyedkazemi, Pharm.D.
Chief Development Officer
Chief Development Officer
52.75K
-1.72%
Mr. Patrick (Pat) Machado, J.D.
Mr. Patrick (Pat) Machado, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
8.82K
--
Dr. Laurent Fischer, M.D.
Dr. Laurent Fischer, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Szilard Kiss, M.D.
Dr. Szilard Kiss, M.D.
Director
Director
--
--
Dr. Rabia Gurses Ozden, M.D.
Dr. Rabia Gurses Ozden, M.D.
Chief Medical Officer
Chief Medical Officer
--
-100.00%
Dr. Reed V. Tuckson ,M.D.
Dr. Reed V. Tuckson ,M.D.
Independent Director
Independent Director
--
--
Ms. Linda M. Rubinstein
Ms. Linda M. Rubinstein
Chief Financial Officer
Chief Financial Officer
--
--
Mr. James P. (Jim) Scopa, J.D.
Mr. James P. (Jim) Scopa, J.D.
Independent Director
Independent Director
--
--
Dr. C. David Nicholson, Ph.D.
Dr. C. David Nicholson, Ph.D.
Independent Director
Independent Director
--
--
Mr. Jason L. Mitchell
Mr. Jason L. Mitchell
Chief Commercial Officer
Chief Commercial Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Setareh (Star) Seyedkazemi, Pharm.D.
Dr. Setareh (Star) Seyedkazemi, Pharm.D.
Chief Development Officer
Chief Development Officer
52.75K
-1.72%
Mr. Patrick (Pat) Machado, J.D.
Mr. Patrick (Pat) Machado, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
8.82K
--
Dr. Laurent Fischer, M.D.
Dr. Laurent Fischer, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Szilard Kiss, M.D.
Dr. Szilard Kiss, M.D.
Director
Director
--
--
Dr. Rabia Gurses Ozden, M.D.
Dr. Rabia Gurses Ozden, M.D.
Chief Medical Officer
Chief Medical Officer
--
-100.00%
Dr. Reed V. Tuckson ,M.D.
Dr. Reed V. Tuckson ,M.D.
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 16 de mai
Atualizado em: sex, 16 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BML Capital Management LLC
14.64%
TCG Crossover Management, LLC
8.60%
Franklin Advisers, Inc.
8.43%
Principia Wealth Advisory, LLC
8.12%
BlackRock Institutional Trust Company, N.A.
6.29%
Other
53.93%
Investidores
Investidores
Proporção
BML Capital Management LLC
14.64%
TCG Crossover Management, LLC
8.60%
Franklin Advisers, Inc.
8.43%
Principia Wealth Advisory, LLC
8.12%
BlackRock Institutional Trust Company, N.A.
6.29%
Other
53.93%
Tipos de investidores
Investidores
Proporção
Investment Advisor
46.39%
Investment Advisor/Hedge Fund
15.91%
Individual Investor
12.20%
Private Equity
6.88%
Venture Capital
5.02%
Hedge Fund
2.57%
Research Firm
2.54%
Corporation
0.87%
Bank and Trust
0.12%
Other
7.51%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
192
19.32M
92.50%
-3.22M
2025Q1
200
18.99M
90.93%
-3.09M
2024Q4
197
18.17M
87.35%
-2.16M
2024Q3
205
18.40M
88.51%
-3.17M
2024Q2
198
18.25M
87.99%
-2.40M
2024Q1
209
17.03M
82.27%
+429.10K
2023Q4
203
6.60M
65.29%
-2.40M
2023Q3
243
6.95M
68.86%
-2.49M
2023Q2
271
6.98M
69.47%
-2.29M
2023Q1
309
6.72M
66.88%
-3.80M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
BML Capital Management LLC
3.06M
14.64%
+315.21K
+11.49%
May 19, 2025
TCG Crossover Management, LLC
1.80M
8.6%
--
--
Mar 31, 2025
Franklin Advisers, Inc.
1.76M
8.43%
--
--
Mar 31, 2025
Principia Wealth Advisory, LLC
1.70M
8.12%
+366.15K
+27.52%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.31M
6.29%
-57.92K
-4.22%
Mar 31, 2025
Stern (Augustus)
1.12M
5.35%
+1.12M
--
Oct 29, 2024
Frazier Life Sciences Management, L.P.
1.07M
5.12%
--
--
Mar 31, 2025
Rush (Ryan Bradford)
1.05M
5.03%
+1.05M
--
Dec 17, 2024
The Vanguard Group, Inc.
1.03M
4.93%
-1.76K
-0.17%
Mar 31, 2025
5AM Ventures
541.67K
2.59%
--
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
iShares Micro-Cap ETF
0.01%
Fidelity Enhanced Small Cap ETF
0%
iShares Russell 2000 ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Global X Russell 2000 ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
ProShares Hedge Replication ETF
0%
ProShares UltraPro Russell2000
0%
Dimensional US Core Equity 1 ETF
0%
Proshares Ultra Russell 2000
0%
Ver Mais
iShares Micro-Cap ETF
Proporção0.01%
Fidelity Enhanced Small Cap ETF
Proporção0%
iShares Russell 2000 ETF
Proporção0%
iShares Core S&P Total U.S. Stock Market ETF
Proporção0%
Global X Russell 2000 ETF
Proporção0%
DFA Dimensional US Core Equity Market ETF
Proporção0%
ProShares Hedge Replication ETF
Proporção0%
ProShares UltraPro Russell2000
Proporção0%
Dimensional US Core Equity 1 ETF
Proporção0%
Proshares Ultra Russell 2000
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Mar 18, 2024
Merger
10<1
Mar 18, 2024
Merger
10<1
Mar 18, 2024
Merger
10<1
Mar 18, 2024
Merger
10<1
Data
Tipo
Proporção
Mar 18, 2024
Merger
10<1
Mar 18, 2024
Merger
10<1
Mar 18, 2024
Merger
10<1
Mar 18, 2024
Merger
10<1
